Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...

A trend in gene therapy setbacks continues as Vertex Pharmaceuticals gave Verve Therapeutics back the rights to a liver disease gene editing program. The research and development deal dates back to ...

Vertex AI is a fully-managed, unified AI development platform for building and using generative AI. This repository is designed to help you get started with Vertex AI. Whether you're new to Vertex AI ...